702628-84-0

Basic information

• Product Name: 3-(4-fluorophenoxy)azetidine(SALTDATA: 1.12HCl 0.45H2O)
• Synonyms: 3-(4-fluorophenoxy)azetidine(SALTDATA: 1.12HCl 0.45H2O)
• CAS NO: 702628-84-0
• Molecular Formula: C₉H₁₀FNO
• Molecular Weight: 167.1802032
• Mol File: 702628-84-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 109℃
• Appearance: /
• Density: 1.188
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-(4-fluorophenoxy)azetidine(SALTDATA: 1.12HCl 0.45H2O)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-fluorophenoxy)azetidine(SALTDATA: 1.12HCl 0.45H2O)(702628-84-0)
• EPA Substance Registry System: 3-(4-fluorophenoxy)azetidine(SALTDATA: 1.12HCl 0.45H2O)(702628-84-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 702628-84-0(Hazardous Substances Data)

Usage

General Description

3-(4-fluorophenoxy)azetidine is a chemical compound commonly used in the pharmaceutical industry. It is available in the form of a salt, with a composition of 1.12HCl and 0.45H2O. 3-(4-fluorophenoxy)azetidine(SALTDATA: 1.12HCl 0.45H2O) is a derivative of azetidine, a four-membered heterocyclic ring containing nitrogen. The presence of a fluorophenoxy group in 3-(4-fluorophenoxy)azetidine makes it suitable for use in various medications. It is often utilized as an intermediate in the synthesis of drugs or as a building block for the preparation of other organic molecules. The salt form of 3-(4-fluorophenoxy)azetidine enhances its stability and solubility, making it easier to handle in a laboratory setting and facilitating its incorporation into pharmaceutical formulations.

Downstream Products

• 1332302-42-7 1-(3-bromophenyl)-3-(4-fluorophenoxy)azetidine 
• 1332302-51-8 2-chloro-6-(3-(4-fluorophenoxy)azetidin-1-yl)pyridine 
• 1332302-44-9 3-((5-fluoro-2-(3-(4-fluorophenoxy)azetidin-1-yl)pyrimidin-4-yl)amino)-N-methylbenzamide 
• 1448717-37-0 2-[3-(4-fluoro-phenoxy)-azetidin-1-ylmethyl]-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1380753-32-1 methyl 5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinate 

Relevant articles and documents

Triazinone compound and T-type calcium channel inhibitor

There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R1 is H or C1-6 alkoxy, etc., each of L1 and L2 is independently a single bond or NR2, etc., L3 is C1-6 alkylene, etc., A is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C3-11 cycloalkylene, etc., D is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors

Phosphodiesterase 9A inhibitors have shown activity in preclinical models of cognition with potential application as novel therapies for treating Alzheimers disease. Our clinical candidate, PF-04447943 (2), demonstrated acceptable CNS permeability in rats with modest asymmetry between central and peripheral compartments (free brain/free plasma = 0.32; CSF/free plasma = 0.19) yet had physicochemical properties outside the range associated with traditional CNS drugs. To address the potential risk of restricted CNS penetration with 2 in human clinical trials, we sought to identify a preclinical candidate with no asymmetry in rat brain penetration and that could advance into development. Merging the medicinal chemistry strategies of structure-based design with parallel chemistry, a novel series of PDE9A inhibitors was identified that showed improved selectivity over PDE1C. Optimization afforded preclinical candidate 19 that demonstrated free brain/free plasma ≥1 in rat and reduced microsomal clearance along with the ability to increase cyclic guanosine monophosphosphate levels in rat CSF.

ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN

The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.